Moore, A.M., Einhorn, L.H., Estes, D., Govindan, R., Axelson, J., Vinson, J., Breen, T.E., Yu, M. and Hanna, N.H. (2006) Gefitinib in Patients with Chemo-Sensitive and Chemo-Refractory Relapsed Small
Cell Cancers: A Hoosier Oncology Group Phase II Trial. Lung Cancer, 52, 93-97. http://dx.doi.org/10.
1016/j.lungcan.2005.12.002

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.